Viking Therapeutics is at the center of acquisition speculation as large pharmaceutical firms hunt for late-stage obesity assets to challenge the market dominance of Eli Lilly and Novo Nordisk.
Back
Viking Therapeutics stock has 215% upside on takeover talk
Viking Therapeutics Inc. (VKTX) is emerging as a prime takeover target for major pharmaceutical companies, driven by promising clinical data for its obesity drug candidate, VK2735. With a dual-agonist approach that rivals existing market leaders, analysts see a potential 215% upside to the stock from its current $30 price, largely fueled by the prospect of an acquisition.
"For large pharma companies, there aren't many late-stage obesity assets left to buy," noted Prosper Junior Bakiny, an analyst with positions in the sector. This scarcity makes Viking, with its dual injectable and oral programs, particularly attractive.
The company's lead candidate, VK2735, is a GLP-1 and GIP dual agonist, a mechanism similar to Eli Lilly's Zepbound. A Phase 2 trial of Viking's injectable version showed up to 14.7% average weight loss after 13 weeks. The oral version, a key differentiator, produced a 12.2% weight loss in a similar study. The company has fully enrolled its Phase 3 VANQUISH trial for the injectable and plans to initiate Phase 3 trials for the oral tablet later this year.
The strategic value lies in acquiring a de-risked, late-stage asset in a market projected to exceed $100 billion annually. An acquisition would allow a larger firm to bypass early-stage development risk and immediately compete with Eli Lilly and Novo Nordisk. Viking's current market capitalization remains significantly lower than the multi-billion dollar valuations of established obesity franchises, making a buyout a financially viable alternative to building a program from the ground up.
The Competitive Landscape
The land rush for effective obesity treatments has created a competitive environment. Eli Lilly and Novo Nordisk are the current titans, but a wave of new entrants is coming. Amgen is advancing its monthly injectable, MariTide, through pivotal studies, while Roche is moving its own candidate, CT-388, into Phase 3. Viking's VK2735 stands out due to its strong efficacy data and the strategic advantage of having both oral and injectable formulations.
Financial Position and Valuation
Unlike many clinical-stage biotech firms, Viking possesses a relatively strong balance sheet. The company ended the first quarter of 2026 with approximately $603 million in cash and investments, which it believes will fund operations into 2028. This financial runway gives Viking significant leverage in any partnership or acquisition negotiations, reducing pressure for a quick, dilutive financing deal. Wall Street consensus places a $95 price target on the stock, reflecting the high value of VK2735 if it continues to produce competitive data.
Risks and Roadblocks
Despite the bullish outlook, an acquisition is not guaranteed. The obesity market is becoming increasingly crowded, and large pharmaceutical takeovers are unpredictable. Viking still faces significant execution hurdles, including scaling up manufacturing, navigating the final stages of Phase 3 trials, generating long-term safety data, and securing favorable reimbursement from payers. The company currently has no approved products and generates no meaningful revenue, making its valuation almost entirely dependent on the future success of VK2735.
This article is for informational purposes only and does not constitute investment advice.
